Valuation: Inventiva

Market Cap 672M 766M 635M 579M 1.08B 73.42B 1.09B 7.6B 2.94B 37.51B 2.88B 2.81B 121B P/E 2026 *
-4.04x
P/E 2027 * -3.64x
Enterprise Value 553M 630M 522M 476M 891M 60.37B 897M 6.25B 2.42B 30.84B 2.36B 2.31B 99.12B EV / Sales 2026 *
81.3x
EV / Sales 2027 * 0.98x
Free-Float
89.08%
Yield 2026 *
-
Yield 2027 * -
1 day+1.40%
1 week-9.52%
Current month-25.06%
1 month-26.68%
3 months+1.05%
6 months-42.00%
Current year-21.94%
1 week 2.68
Extreme 2.685
3.14
1 month 2.68
Extreme 2.685
4.12
Current year 2.68
Extreme 2.685
5.81
1 year 2.68
Extreme 2.685
5.81
3 years 1.45
Extreme 1.448
5.81
5 years 1.45
Extreme 1.448
12.92
10 years 1.45
Extreme 1.448
15.58
Manager TitleAgeSince
Chief Executive Officer 53 01/10/2025
Director of Finance/CFO 59 22/04/2026
Chief Operating Officer - 31/08/2026
Director TitleAgeSince
Director/Board Member 76 01/02/2017
Director/Board Member 63 27/05/2019
Director/Board Member 52 01/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
+1.40%-9.52% - - 766M
-3.30%+1.50%+57.79%+99.14% 72.26B
+1.25%-3.01%+37.83%+87.66% 60.24B
+2.12%+5.26%+35.69%+23.40% 27.73B
-3.06%-1.81%-14.01%+357.24% 25.73B
-0.75%+2.56%+0.45%-3.28% 24.75B
+0.40%+0.75%+23.72%-11.33% 20.74B
-1.70%-2.12%+150.24%+326.97% 15.06B
+0.36%-0.34%+48.98%+167.40% 14.41B
+0.21%+1.17%-3.95%+512.06% 14.23B
Average -0.31%+0.44%+37.41%+173.25% 30.57B
Weighted average by Cap. -0.76%+0.31%+38.16%+132.99%

Financials

2026 *2027 *
Net sales 6.8M 7.75M 6.42M 5.85M 10.96M 743M 11.03M 76.85M 29.77M 379M 29.09M 28.47M 1.22B 108M 123M 102M 92.63M 173M 11.75B 175M 1.22B 471M 6.01B 460M 451M 19.3B
Net income -151M -172M -143M -130M -244M -16.52B -245M -1.71B -662M -8.44B -647M -633M -27.12B -96.13M -110M -90.79M -82.74M -155M -10.5B -156M -1.09B -421M -5.36B -411M -402M -17.24B
Net Debt -120M -136M -113M -103M -193M -13.05B -194M -1.35B -523M -6.67B -511M -500M -21.43B -567M -646M -535M -488M -913M -61.91B -920M -6.41B -2.48B -31.63B -2.43B -2.37B -102B
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
73
Date Price Change
25/09/26 €2.900 +1.40%
24/09/26 €2.860 -3.87%
23/09/26 €2.975 -2.14%
22/09/26 €3.040 -3.18%
21/09/26 €3.140 -2.03%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.845EUR
Average target price
9.856EUR
Spread / Average Target
+246.43%

Quarterly revenue - Rate of surprise